Healthcare Stocks: 2 To Buy, 1 To Avoid

Investors traditionally think of healthcare stocks as being highly defensive, due to the old adage: medical care is always needed, even in a bad economy.  In recent years, though, the sector has become more cyclical as more biotech companies have joined the traditional staple of pharmaceutical stocks.  While many cry that healthcare isn’t the ‘safety net’ it once was, these newcomers do increase the growth options that investors have at their disposal.  Over the past year, the sector as a whole has gained 13.6 percent, being outgained by only consumer defensive and technology stocks.

One pharma company that has outperformed its peers during this time period is Allergan, Inc. (NYSE: AGN), returning almost 17 percent.  This is not your typical healthcare stock, as the company’s primary focus is on tending to the needs of the ‘cosmetically challenged’.  AGN is the manufacturer of Botox, which accounts for 83 percent of total revenues.  In recent years, the company has fared well from the ‘Botox boom’, which is a term used to describe a worldwide expansion of discretionary spending on beautifying products.  In fact, AGN has noted that sales of Botox, dermal fillers, and breast aesthetics have increased 17 percent since last spring.  Moreover, recent FDA approvals now allow Botox to be used to treat chronic migraines, spinal chord injuries, and multiple sclerosis-related health problems.

The company’s executives are applauding this decision, as around half of all Botox usage is for therapeutic purposes, so these approvals should have a meaningful effect on AGN’s bottom line.  Over the past 5 years, revenues have grown at a compound annual growth rate of 12.1 percent, which is quite splendid considering its closest competitors are in the single digits.  Moreover, EPS has grown by an astounding 87 percent during this same period.  AGN currently pays a small dividend with a yield of 0.2 percent, though this high EPS growth signifies that yields may rise in the future.  Moreover, the company holds hardly any debt – with a D/E ratio of 0.3 – in an industry where many firms are indebted 2-3 times their equity.  Large hedge fund managers like Jacob Gottlieb and Michael Karsch are long AGN.  These details coupled with the fact that the company recently released impressive earnings – Q1 profits rose 45 percent – means that now may be the best time to get into AGN.

Warren Buffett

Essentially the polar opposite of AGN, Johnson & Johnson (NYSE: JNJ) is the world’s most diversified healthcare company.  A leading producer of everything from Band-Aids to baby powder, it seemed that this company hit a pretty hard wall of saturation, as annual revenues lay stagnant near $62 billion between 2007 and 2010.  Surprisingly, JNJ grew its revenues by 6 percent last year; this was a result of a spike in demand from BRIC nations, and the company’s acquisition of the vaccine biotech Crucell NV.  Shares of JNJ seem to be slightly overvalued at the moment, as its current P/E (18.7X) is above its 10-year historical average of 18.1X.  P/B and P/CF ratios tell a similar story.  With its new CEO Alex Gorsky taking reins of JNJ last week, the stock has risen to over $65 dollars a share.  Adding icing to its proverbial cake, the company also pays out a nice dividend yield of 3.5 percent. Hedge funds love this stock, as moguls Warren Buffett and Ken Fisher currently hold it.  If all of these reasons fail to convince you on JNJ, the track records of these two managers should garner your faith.

A member of “Big Pharma,” Bristol-Myers Squibb (NYSE: BMY) is a different animal than JNJ or AGN.  The company primarily researches, develops, and sells pharmaceutical drugs for a wide range of disorders and diseases.  In contrast to many of its competitors, it has exited general healthcare businesses to take a greater focus on its in-house drug development.  Over the past three years, shares of BMY have jumped almost 75 percent, as the company displayed a strong collection of drugs like Plavix and Abilify, though both drugs lose their patents later this year.  Additionally, it is projected that every single one of the drugs in BMY’s pipeline will lose exclusivity by 2017; a date that is sooner than almost all other mega-caps in the healthcare sector.  If this long-term danger wasn’t enough, slow revenue growth and overvaluation indicators do not motivate investors to buy BMY in the short to intermediate-terms either.  The company’s 3-year average revenue growth (6.2%) is below the industry average of 6.9 percent, while its P/E (14.9X) and P/CF (12.0X) ratios are both higher than the industry mark.  If that wasn’t enough, hedge funds have a particular distaste for JNJ stock.  Of the eight managers who currently hold at least 2 percent of their portfolios in JNJ, 6 elected to downsize their holdings rather significantly.  Some of these managers include Buffett, Kerr Neilson, and John Osterweis.

To make a profit off of these three stocks, investors can use pairs trading, by going long AGN/short BMY or long JNJ/short BMY.  While some may disagree on which strategy to use, most can agree on the fact that BMY is the worst stock of the three.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!